Physician profile
Stella Lee
NPI 1780355065
$7,095.51
in general payments reported to CMS, 2019-2025
21 companies · $3,751 in 2025
The $3,751 reported for 2025 was more than what 97% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $15.24 · 2024: $3,330 · 2025: $3,751.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,880 · Education: $216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,879.67 |
| Education | $215.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $1,144.24 | 2024-2025 | Zoryve |
| Abbvie INC. | $868.85 | 2024-2025 | |
| Incyte Corporation | $624.70 | 2024-2025 | Opzelura |
| Ucb, INC. | $617.35 | 2024-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $526.02 | 2024-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $471.08 | 2024-2025 | |
| Janssen Biotech, INC. | $384.76 | 2024-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $369.28 | 2024-2025 | Sotyktu |
| Dermavant Sciences, INC. | $356.20 | 2024 | Vtama |
| Almirall LLC | $301.58 | 2024-2025 | Klisyri |
| Sun Pharmaceutical Industries INC. | $246.95 | 2024-2025 | |
| Lilly USA, LLC | $208.97 | 2024-2025 | Ebglyss, Taltz, Olumiant |
| Amgen INC. | $208.90 | 2024-2025 | Otezla |
| Pfizer INC. | $149.57 | 2023-2025 | |
| Galderma Laboratories, L.P. | $120.99 | 2024-2025 | Nemluvio |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $110.68 | 2024-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $97.52 | 2024-2025 | |
| Organon LLC | $95.97 | 2025 | Nexplanon |
| Janssen Scientific Affairs, LLC | $86.97 | 2024 | Tremfya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $82.68 | 2025 | Jublia, Cabtreo |
| Genentech USA, INC. | $22.25 | 2025 | Xolair |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stella Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.